Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2016
At a glance
- Drugs GLPG 1205 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Acronyms ORIGIN
- Sponsors Galapagos NV
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2016 According to a Galapagos NV media release, the company announced results of ORIGIN study.
- 26 Jan 2016 According to a Galapagos NV media release, primary endpoint (Percentage of subjects achieving Mayo clinical remission at Week 8 as measured by Mayo score in the GLPG1205 group versus the placebo group (Mayo score less than or equal to 2 with no individual subscore exceeding 1 point and rectal bleeding score of 0). Change in Mayo of GLPG1205 vs placebo at week 8 compared to baseline) has not been met.